Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab.
Pham
Dat C
DC
Guthrie
Troy H
TH
Villas
Bruce H
BH
Salazar
Elaine
E
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D008297:Male; D012010:Red-Cell Aplasia, Pure / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D013921:Thrombocytopenia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D006454:Hemoglobins; D000074323:Alemtuzumab